Veradermics, Inc (MANE) stock
MANENYSEPharmaceutical PreparationsFiscal year ends December 31
$125.64−2.41 (-1.88%)
Close on Nov 17, 2026Market cap $5.25BP/E –Yield –
Veradermics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
For fiscal 2025 it was -$71.60M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$71.60M | – |
| FY2024 | Dec 31, 2024 | -$23.69M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$14.49M | – |
| Q1 FY2026 | Mar 31, 2026 | -$21.17M | – |
| Q2 FY2025 | Jun 30, 2025 | -$15.64M | – |
| Q1 FY2025 | Mar 31, 2025 | -$13.32M | – |
See a number that looks wrong?